Abstract
Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer that rarely develop distant metastasis but often invade surrounding areas. Due to the limited therapeutic options available, the prognosis of these patients is poor, particularly in those with sarcomatoid histology. Moreover, trimodality treatment of resectable MPM is still controversial with high heterogeneity of clinical outcomes among resected patients and the lack of predictive biomarkers. Genomic studies have showed that MPM tumors are characterized by poor mutational landscapes characterized by minute mutations, rather than driver mutations, that are often missed in comparative genomic hybridization and next-generation sequencing studies.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
